13cisn[4(ethoxycarbonyl)phenyl]retinamide

Dupilumab (REGN-668) is a fully human monoclonal antibody targeting the alpha subunit of the interleukin-4 receptor, thereby inhibiting IL-4 and IL-13 signaling. As a systemic immunomodulator, it has demonstrated efficacy in improving atopic dermatitis.

Rolinsatamab is a fully humanized selective monoclonal antibody that is a potent dual inhibitor of IL-4 and IL-13. Rolinsatamab chimeric antigen receptor sequence T cells. Rolinsatamab can be used to prevent and treat immune diseases.

Manfidokimab (AK120) is a human monoclonal antibody of the IgG4 subclass that specifically targets the interleukin-4 receptor alpha subunit (IL-4Rα). by binding to this shared subunit, Manfidokimab simultaneously blocks the downstream signaling pathways of both interleukin-4 (IL-4) and interleukin-13 (IL-13), and Manfidokimab can be used in studies about moderate to severe atopic dermatitis.

Eblasakimab (ASLAN004) is a humanized monoclonal antibody targeting the IL-13 receptor alpha. By blocking IL-4 and IL-13 signaling through type 2 receptor inhibition, it can be used for studying atopic dermatitis.

Romilkimab (SAR156597) is a chimeric humanized immunoglobulin (Ig) antibody specifically designed to target interleukins 4 and 13 (IL-4 and IL-13) [1].

Rademikibart (CBP-201) is a humanised monoclonal antibody targeting IL-4Rα (KD = 20.7 pM) that does not interact with IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signalling pathways, TF-1 cell proliferation, and TARC production in PBMCs, making it useful for studying Th2-type inflammatory diseases.

Tilrekimig is a monoclonal antibody that targets human interleukin 4 (IL-4), interleukin 13 (IL-13), and TSLP (thymic stromal lymphopoietin). It shows potential for research applications in allergic and inflammatory conditions, such as asthma and atopic dermatitis.

Ompekimig is a humanized immunoglobulin monoclonal antibody targeting human interleukin 4 (IL-4) and interleukin 13 (IL-13). It shows potential for use in immune-mediated inflammatory diseases such as asthma and atopic dermatitis.